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As every school child knows, chameleons can regen-
erate a lost tail. Indeed, regrowth of appendages is a not 
uncommon phenomenon among other lower animals. In 
mammals, however, regenerative capacity is much more 
restricted. The special regenerative capability of the 
mammalian liver has been recognized over millennia, as 
epitomized by the ancient legend of Prometheus. The 
explanation for liver regeneration has been of interest to 
investigators for more than a century. With the conver-
gence in our laboratory of two lines of inquiry more than 
a third of a century ago, this quest for understanding 
received a major stimulus. 
The first theme concerned the cross regulation of the 
liver and nonhepatic splanchnic organs, especially in-
volving insulin in the pancreaticohepatic axis (1-3). In 
experiments with Eck's fistula (portacaval sh1.lllt), the 
liver's first pass exposure to the hOr1llone and nutri-
ent-rich venous blood coming from all of the other 
splanchnic organs was eliminated. Liver atrophy already 
was well-known to be caused by this operation (4), but 
was generally ascribed to reduction in total hepatic blood 
flow, rather than to the loss of a particular kind of blood. 
Although this "flow hypotheses" of portal physiology 
was established dogma well into the 1960s, proving or 
disproving it was quite another matter. In 1961, after a 
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lifetime of largely futile examination of the subject, 
Bollman (5) wrote, "In the 83 years since it was first 
reported, the Eck fistula has been reasonably successful 
in hiding its secrets as well as giving rise to many 
additional questions fundamental to an understanding 
of the functions of the intestine, liver and brain." 
The canine Eck fistula investigations coalesced with 
our second research theme of liver transplantation in 
experiments to determine in dogs the optimum anatomic 
positioning and revascularization of orthotopic (6) or 
auxiliary hepatic allografts (7). Provision of a normal 
portal blood supply was shown to be important with 
either kind of transplant procedure, but uniquely so 
with the auxiliary hepatic operation after which two 
livers coexisted in the same dog (Fig. lA). It was found 
that the organ through which host splanchnic venous 
blood was directed retained its normal size, whereas the 
competing organ (whether host or graft) shrank and 
deteriorated functionally, in spite of providing it with 
portal venous inflow from alternative nonsplanchnic 
sources (7, 8). The shrunken portaprival liver (Fig. 2) 
showed other characteristics that were indistinguish-
able from an Eck fistula liver. We concluded that there 
must be growth-modulating substances in splanch-
nic venous blood that controlled the liver's size and 
presumably the quality of its function. 
These substances came to be known as hepatotrophic 
factors and, although they remained unidentified for 
another 10 yr, it was clear that they were largely 
consumed during a single passage through the first 
liver to which they were exposed, leaving little for its 
atrophic partner. Recognition of the double liver prin-
ciple, whereby one liver d9minates the other by its 
avid clearance of hepatotrciphic factors, subsequently 
had a pervasive impact on the study of liver physiology 
in general and hepatic growth factors in particular, 
but this was slow to evolve. In extensions of the pri-
mary discovery, a series of non transplant models was 
developed (9-11) in which the animal's own liver was 
divided into competing fragments (Fig. 1B-D). With 
these models, and particularly the final one shown in 
Figure 1D (see later), eight growth factors with potent 
hepatotrophic effects (11-21) as well as two with 
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FIG. 1. Growth factor detection with coexisting liver and Eck fistula 
models alone or in combination: (A) auxiliary liver transplantation; (B) 
partial portacaval transposition; (e) splanchnic venous division; (D) 
Eck fistula plus selective infusion of tested substance. 
the opposite action (22, 23) were identified (Ta-
ble 1). 
The first clearly delineated hepatotrophic factor was 
insulin (11), followed 4 yr later (12) by the cytosol ofliver 
cells containing the ALR, which is the principal focus of 
this review. When infused by itself into the defunction-
alized hilar portal vein after portacaval shunt, each of 
the eight substances could prevent the hepatocyte and 
whole organ shrinkage caused by the Eck fistula. In 
addition, they all caused a hyperplastic response similar 
in amplitude but more sustained than in the regener-
ation response following a moderate partial hepa-
tectomy. The development of the in vivo Eck fistula 
assay (Fig. 1D) was critical for the identification and 
study of these eight hepatotrophic factors because only 
two of them, TGF-a and HGF, stimulate mitoses in 
tissue culture. 
The most elusive of the six nonmitogenic "occult" 
growth factors was the ALR, of which there was evidence 
in the hyperplastic livers of weanling rats, or in the 
residual liver fragment of adult animals of several 
species after partial hepatectomy. Its purification to 
> 800,000 (13-16) and cloning (17) after 16 yr of 
continuous effort in our laboratories has added another 
important component to the complex network ofmodu-
lators, both stimulatory and suppressive, that regulate 
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hepatocyte proliferation and hepatic regeneration at the 
organ level. In these days of cellular and molecular 
biology, it is striking that the two operations of porta-
caval shunt (Eck's fistula) (24) and auxiliary liver 
transplantation (25) described in dogs 78 yr apart played 
an indispensable role in this development. 
The new growth factor ALR is a unique heat-stable 
peptide whose gene exhibits a 50% homology with the 
dual-function nuclear yeast gene ERVI (17). The ERVI 
gene is required for oxidative phosphorylation (respira-
tory chain) and is essential for mitosis, which ceases in 
3 to 4 days after gene deletion in Saccharomyces 
cerevisiae (26). If, as we suspect, ALR is the mammalian 
homolog of ERV1, it is apt to be a major growth-
regulatory gene. 
Just as an understanding of the regulation of bone 
marrow proliferation by lineage-specific hematopoietic 
growth factors has led to major advances in the safety 
and success and significant reductions in the cost of 
bone marrow transplantation (27-29), a similar under-
standing of the regulation of hepatocyte proliferation 
and hepatic regeneration will have immediate applica-
tions in numerous clinical settings. These could include· 
the treatment of fulminant hepatic failure, and compli-
cations of hepatic surgical procedures including both 
portasystemic shunt operations and transplantation. 
The ability to influence hepatic mitotic activity and the 
cell cycle may also dramatically influence the choices of 
strategies for hepatic gene therapy, some of which 
currently require surgical partial hepatectomy to induce 
the necessary hepatocyte proliferation (30). 
In the sections that follow, we review the patho-
physiology of the often-maligned Eck fistula and em-
phasize the unique role it has played in the search for 
and study of hepatocyte growth-regulatory factors. We 
will then attempt to place ALR in an appropriate 
perspective in the expanding universe of hepatic growth 
factors. 
THE PATHOPHYSIOLOGY OF ECK'S FISTULA 
The Eck fistula liver after portacaval shunt was 
thought - until about 30 yr ago - to function normally 
except for hyperammonemia. This view was inconsistent 
with the striking hepatocyte atrophy (to half size), deg-
lyogenation and fatty infiltration caused by the oper-
ation in all species studied, including human beings 
(31-34). At the same time,'there is a tripling ofliver cell 
renewal (11, 34, 35). In dogs, both the atrophic and 
hyperplastic alterations are complete within 4 days and 
remain stable thereafter (Tahle 2). The ultrastructure of 
the hepatocytes shows a striking disruption of the rough 
endoplasmic reticulum and depletion of the ribosomes 
(12,31-38), explaining a reduced synthesis of cholesterol 
and other lipid moieties, bile acids, urea and, pre-
sumably, essentially all metabolites of hepatic origin 
(summarized in reference 33). Lowered activity of the 
hepatic microsomal mixed function enzyme system for 
which multiple cytochrome P-450 and P-448 species 
serve as terminal oxidases account for other subtle but 
cumulatively massive degradations in hepatic function 
(33). 
t 
. 
•. 
t 
. 
1 
J 
: 
"-
HEPATOLOGY Vol. ~lI No.3, 1994 FRANCAVILLA ET AL. 749 
FIG. 2. The auxiliary allograft (right) and the recipient dog's own liver (left) 45 days after the experimental transplantation was performed 
in 1964. Immunosuppression was with azathioprine, and there was no histopathological evidence of rejection. Note the well-preserved but 
dimensionally reduced general structure ofthe allograft. The gallbladder did not shrink proportionately. (By permission ofStarzl TE, et al. Ann 
Surg 1964;160:411-438.) 
TABLE 1. Growtn factors revealed by studies in Eck fistula 
models (1994) 
Stimulatory 
Hormones: 
Insulin 
Growth factors: 
Cytosol substrate and ALR 
IGF II 
TGF-aa 
ed~ 
Immunosuppressants: 
Cyclosporine 
FK 506 ' 
Immunophilins: 
FKBP12 
Inhibitory 
Growth factors: 
TGFl3b 
Immunosuppression: 
Rapamycinb 
aMitogenic in tissue culture. 
blnhibitory in tissue culture. 
Reference no • 
11 
12-17 
18 
18 
18 
19 
20 
21 
22 
23 
THE DOUBLE LIVER FRAGMENT MODELS 
The evidence of portal hepatotrophic factors obtained 
in the 1963 auxiliary liver transplant experiments was 
verified in nontransplant models developed over the next 
decade in which the animal's own liver was divided into 
two fragments, differing in the quality of blood delivered 
to the right and left main portal vein branches. The flow 
hypothesis of portal physiology that already had been 
toppled was now routed by a series of complex double 
liver fragment experiments showing that the least 
hepatotrophic blood was that from the inferior vena cava 
(9, 10) (Fig. IB), and the most hepatotrophic was from 
TABLE 2. Evolution of Eck fistula changes after operation 
Labeled. 
Time in days hepatocytes/l,OOO Cell size units 
0 1.5 0.18 
1 1.5 0.17 
2 1.9 0.15 
3 3.2 0.12 
4 4.5 0.09 
·60 4.5 0.09 
Composite references: 11,12,34,36 
the upper splanchnic viscera, which included the pan-
creas (10, 31, 39) (Fig. Ie). The "liver-supporting" 
qualities of the nutrient-rich intestinal venous affluent 
were between those extremes (31,39) (Fig. Ie). It also 
was found that the canine liver tissue with first-pass 
exposure to endogenous insulin had :3 to 4 times the 
basal cell renewal of the atrophic insulinoprival frag-
ments (15 vs. 4.5/1,900 hepatocytes with thymidine 
incorporation) and a superior ability to regenerate after 
hepatic resection (36). All of these so-called hepa-
totrophic advantages were lost. after surgical pancre-
atectomy or the production of alloxan or streptozotocin 
diabetes (31, 36, 39). Thus, although insulin was poorly 
mitogenic-if at all-to hepatocytes in tissue culture 
(40-42), it was the principal portal hepatotrophic can-
didate from 1973 onward (10). 
THE ECK FISTULAIDOUBLE LIVER ASSAY IN THE 
HEPATOTROPHIC FACTOR SEARCH 
The dominance of insulin notwithstanding, there was 
evidence in canine double liver (31, 36, 39) and selective 
evisceration experiments (43, 44) of other cumulatively 
significant splanchnic growth factors, principally of 
intestinal origin. The inability to separate these effects 
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from those of insulin, or even to prove that insulin alone 
was hepatotrophic prompted development of an addi-
tional double-fragment canine model (11, 34), in which 
the liver was first deprived of all portal inflow by 
performing portacaval shunt. Then, an infusion catheter 
was inserted into a tied-off portal vein branch, and test 
substances were injected regionally into the vein's 
distribution. In essence, this created a sophisticated 
double liver preparation in which the effect of a single 
agent could be determined in one liver region and its 
effects judged by comparison with the uninfused (con-
trol) side (Figure 1D). The hepatotrophic end points in 
this growth factor assay were the same as in the other 
. double fragment models: hepatocyte size, rate of cell 
renewal and quality of ultrastructure. 
Hormones 
A potent hepatotrophic effect of insulin was easily 
demonstrable with the Eck fistula assay (11, 34). The 
emergence of insulin and the demonstration by Short 
and Lieberman (45) that hormone cocktails could drive 
r~sting livers into mitosis prompted a flurry of hormone-
regulatory hypotheses to explain hepatic regeneration 
(45-47), supported by claims that glucagon was syner-
gistic with insulin (48). However, the hypothesis was 
undermined by the inability to confirm a glucagon effect 
in the canine Eck fistula model (11, 34) or in selective 
evisceration experiments in dogs (43, 44), and by failure 
with the Eck fistula during the next 15 yr to add more 
hormones to the list ofhepatotrophic molecules with the 
possible exception of the weakly hepatotrophic thyroxin 
(T 3) (18). 
In the meanwhile, the demonstration that several 
hormones and nonhormonal agents were mitogenic to 
cultured hepatQcytes contributed to a switch to in vitro 
screening technologies (41, 49,50) by most investigators 
in the growth factor field, a consensus movement that 
we resisted. Wamed by our experience with insulin that 
growth factor potency in vivo and mitogenicity in tissue 
culture were not correlated, we continued to depend on 
in vivo testing as the ultimate benchmark in all further 
growth factor research. 
ALR 
With the eclipse of the multiple hormone hypothesis, 
our attention in 1978 turned upstream to the liver, 
which had been suspected for a long time to be a source 
of self-perpetuating paracrine or humoral growth fac-
tor(s) (51). Soon after the classic description in 1931 by 
Higgins and Anderson (52) of hepatic regeneration in 
rats after 70% hepatectomy, McJunkin and Breuhaus 
(53) reported that the modest mitotic response to a 
limited (30% to 45%) hepatectomy was significantly 
enhanced with an intraperitoneal injection 2 days post-
operatively of homogenized homologous rat liver. In 
Helsinki, Teir and Ravanti (54) and Teir's postgraduate 
student, Blomquist (55), associated this regeneration-
augmenting activity with the heightened mitoses that 
were in the weanling or regenerating posthepatectomy 
livers from which their homogenates were made. The 
mirror image observations also were made that these 
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homogenates were most effective when injected into 
weanling rats who had naturally hyperplastic livers-
only equivocally so by 3 mo of age when the hepatic 
hyperplasia in the test animals had abated, and not at all 
in adult rats. This meant that mitoses in the donor liver 
begot hepatic mitoses in the treated animal but only 
when there was a concomitant or previous commitment 
to increased cell renewal for independent reasons. 
However, this evidence of a need for "priming" was 
not fully conceptualized until 1975, when LaBrecque 
and Pesch (56) described "hepatic stimulatory sub-
stance (HSS)" in the cytosol of weanling or regenerating 
rat livers. The HSS did not affect the resting adult liver 
when injected intraperitoneally, but it significantly 
augmented the regeneration after a small hepatectomy 
in these animals. In analogous canine experiments, 
using regenerating posthepatectomy liver as a cytosol 
source (57), we confirmed the findings of LaBreque and 
Pesch. By this time, the relatively crude minimum 
hepatectomy model to study the stimulatory activity of 
the liver had survived a half century of scientific 
literature (53-57). It was one of the two in vivo assays 
used subsequently to study purified ALR. 
The other was the Eck fistula assay, the exquisite 
sensitivity of which was established during the crucial 
demonstration in 1979 that dog hepatic cytosol had the 
same hepatotrophic effects as insulin in this model (12). 
The stimulatory activity was maximal in the cytosol 
prepared from hepatic remnants harvested 2 and 3 days 
after resection (12, 57), when peak liver regeneration 
occurs in the canine species (58). Similar to the rat HSS 
of LaBrecque and Pesch (56), the canine "X-factor" was 
heat-stable but destroyed by perchloric acid. The cytosol 
containing it was rich in soluble proteins and other 
cytoplasmic constituents, but free of organelles, cell 
membranes, microsomes, viruses and insulin or glu-
cagon (12). . 
At an international hepatology congress' held in Basel, 
Switzerland in 1979, the history ofhepatotrophic physi-
ology was reviewed, including the latest information 
about the stimulatory qualities of regenerating hepatic 
cytosol and announcement of plans for its purification 
(59). By this time, peer acceptance of the hepatotrophic 
concept was complete. However, overthrow of the deeply 
entrenched "flow hypothesis" had taken more than 15 
yr, leaving scientific corpses and priority disputes in its 
wake. Most importantly, the consensus movement 
during this time toward in vitro cellular as well as 
molecular biological investIgative techniques tended to 
place the previous accomplishments with intact animals 
in an unsophisticated light. The currents of funding 
turned cold for proposals to purify liver cytosol and test 
it along the in vivo lines that had been so fruitful. 
Consequently, all grant applications for the purification 
project were rejected by peer review during the next 15 
yr, invariably with comments about the nonfeasibility of 
the proposal in the hands of the applicants. A shutdown 
was prevented by internal support from the University 
of Pittsburgh and by the fact that an appendiceal 
connection could be made to research funding in 
transplantation. 
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TABLE 3. Preparation of rat ALR" 
Times Initial animal 
Purifica ti on steps Product purification Year assay used 
1. Killing by guillotine, between 7:00 and 8:00 AM. Mince and Cytosol fraction (Cyt-F) 1982 Rats 
then homogenize the liver in 150 mmol/L sodium acetate buffer, 
pH 4.65 (35:100 w/v). 
Ultracentrifuge homogenate at 24,000 g for 30 min at 4° C. 
2. Heat cytosol at 65° C for 15 min. Centrifuge at 30,000 g for Alcohol fraction (OH-F) 32 1983 Rats 
20 min at 4° C, collect supernatant and add to it 6 vol of cold 
ethanol (1 : 6, v/v). Stir at 2_8° C for 2 hr. Centrifuge 30,000 g 
for 20 min at 4° C. Resuspend precipitate in 0.150 mmollL 
ammonium acetate pH = 6. 
3. Filter OH-F through an Amicon membrane with a molecular Mr 30,000 fraction (30 kDa-F) 52 1983 Rats 
weight cutoff of 30,000 Da. 
Collect the filtrate and concentrate it by a 500-Da cutoff Ami-
con membrane. 
4. Lyophilize 30 kDa-F. Resuspend lyophilized 30 kDa-F phos- 150 fraction (F150) 31,000 1985 Rats 
phate buffer 5 mmol/L, pH6, and perfrom chromatography us-
ing mono Q HR 5/5 column with a linear 0-200 mmol/L NaCl 
gradient in phosphate buffer. 
Collect the chromatographic peak at 150 mmol/L NaCI gradient. 
5. Nondissociating PAGE of F 150 Acr F 4 381,000 1987 Rats, dogs 
"Literature of earlier purification steps summarized in reference 14. 
Choice of Stimulatory Cytosol. Beginning in the 
autumn of 1981, U~ yr were invested to obtain a pure 
enough fraction to permit an attempt at sequence 
analysis and cloning (13-16,60). The rat rather than the 
dog was selected as a substrate source because the 
objective was to learn the protein chemistry of the 
purified active substance. How to induce the hepatic 
hyperplasia, without which stimulatory activity was not 
detectable, was the first question. The induction of 
hepatocyte proliferation with T 3 (13, 61) or with hepa-
tectomy were eventually discarded because of concern 
that they would induce hormonal or stress-related arte-
facts, respectively. In 1984, we switched exclusively to 
weanling rats ( < 80 gm, 2 to 3 wk old) as a cytosol source, 
as first recommended by Teir and Ravanti (54); even-
tually more than 10,000 animals were required. Pooling 
of the naturally hyperplastic weanling livers diluted the 
effect of isolated errors in animal selection or variations 
in activity. 
Assay. In agreement with the in vitro results of 
workers elsewhere, the crude cytosol and our earliest 
fractions increased the thymidine incorporation of cul-
tured hepatocytes or hepatoma cells (13, 61). This 
stimulatory property was retained in the purification 
products described by LaBrecque et al. (62, 63). Fleig 
and Ross (64) also reported stimulatory activity of the 
cytosol refinement products, but only if the medium also 
was enriched with epidermal growth factor (EGF). In 
contrast, all fractions prepared by us beyond x 30,000 
purification were inert in vitro with or without EGF (14, 
15), including the highly purified peptide used for cDNA 
cloning (17). At the time, the divergence of our results 
from those of other investigators raised the possibility 
that we had refined away the molecule we were seeking, 
but our results ultimately became part of the uniqueness 
profile of our ALR. 
Uncertainties about in vivo assay also bedeviled the 
research for the first 7 yr. In an egregious error, we 
believed that the highly reproducible canine Eck fistula 
model would be inappropriate to assay the rat peptide. 
With the alternative method of LaBrecque and Pesch 
(56), the variability of the regeneration that normally 
follows a small (34% to 40%) hepatectomy in rats made 
it difficult to quantitate the augmentation of this 
response caused by an intraperitoneal injection of rat 
cytosol or its derivatives. 
After species-nonspecificity of the purified cytosol 
fractions was proved in 1987 (14), we returned to the 
canine Eck fistula model for assay (15). This ended the 
nightmare of attempting to purify a growth factor whose 
growth effects could not be accurately evaluated. Now, 
we were able to confidently proceed from one stage of 
purification to the next. 
Purification. Details of the purification of ALR, as 
well as the years in which improvements were made, are 
summarized in Table 3. The F150 fraction (x 31,000) 
prepared. with FPLC was shown to be stable for > 1 yr, 
permitting its stockpiling. However, the entire supply 
was used up between 1985 and 1987 in futile attempts 
at further purification, without knowing whether the 
activity had been discarded or inadequately assayed. In 
spite of the prodigious effort already made, aban-
donment of the project was discussed for the first time. 
Instead, a fresh start was begun with a newly prepared 
supply of the lyophilyed F150 fraction, using nondisso-
ciating PAGE. Four fractions were produced (Fig. 3), of 
which AcrF 4 (x 381,000 purification) was shown to be 
active by testing with both the minimal hepatectomy 
and Eck fistula models (Fig. 4). When the results from 
these two assays were shown to correlate (15), a 
bottleneck was broken. With the Eck fistula assay, 
hepatotrophic activity could be unambiguously iden-
752 FRANCAVILLA ET AL. HEPATOLOGY September 1994 
Effect of PAGE Fractions on 
DNA Synthesis in 40% PH Rats 
F150 Native PAGE 
60 
Acr F I 
Ac r F· 
s: 10 
I:") 
o 
c Acr-F 4 1 Acr F" 
FIG. 3. Electrophoresis of rat ALR purified 381,000 times, showing augmentation of regeneration (following 40% hepatectomy), only with 
acrylamide fraction 4 (Acr F 4 ). 
Dose-Response Effect on Liver Proliferation of 
Acr-F4 Injected in 40% Hepatectomized Rats and 
in the Left Lobe of Dogs with pes 
~ 
40% P.H. 
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FIG. 4. Correlation ofrat ALR (Acr F 4 ) effect in rat hepatectomy (left) and canine Eck fistula (right) assays. Note that the doses/kg were 10 
times greater or more in the rat than in the dog assay. 
tified in a single test dog. Because the effective dose/kg 
in the canine model was 1/10 to 1/20 of that in the rat 
assay (Fig. 4), the largest total amount needed to test a 
normal size dog, even with high doses, was < 500 ng. 
A murine monoclonal antibody raised against Acr F 4 
and added to Acr F 4 in the Eck fistula infusate eliminated 
the activity contained in this fraction, while having no 
effect on the hepatotrophic activity of IGF II or hepa-
tocyte growth factor (HGF) (Table 4). The same mono-
clonal antibody was useful to further demonstrate the 
specificity of the later x 831,000 purification product, 
which had an estimated molecular weight of 33 kDa (16). 
At the end, the activity of.:.recombinant ALR was 
similarly cancelled by this antibody (see later text). 
Cloning of ALB. In June 1989, a meeting in Pitts-
burgh with officials of the Toyobo Corporation, Osaka, 
Japan, was arranged by Dr. Yuichi Iwaki, Professor of 
Surgery, University of Pittsburgh. The first shipment of 
the purified rat ALR was sent to Japan in March 1990. 
The fraction (Acr F 4) (Fig. 3) contained three residual 
bands of 14, 30 and 35 kDa, as well as a band of 
thioredoxin. Its characteristics are summarized in Table 
5. The procedures had involved the following successive 
steps: ethanol precipitation, ultrafiltrati<?n through an 
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TABLE 4. Specific activity of mAb against native ALR tested in the Eck fistula model" 
Labelled hepatocytes (per thousand) 
Dog no. Infusate Side infused Left Right 
1 HGF 50 ng/kglday Left 12.0 ± .01 4.7 ::t: 0.12 
2 HGF + 50 ng/kg/day mAb + Left 11.6 
3 IGF II, 50 ng/kg/day Left 12.2::t: .01 4.37 ::t: 0.51 
4 IGF II, 50 ng/kg/day mAb + Right 11.1 
5 Acr F 4 50 ng/kg/day Left 13.8 
Act- F 4 50 ng/kglday mAb + Right 4.2 
"Infusions for 4 days immediately after the completely diverting portacaval shunt. 
Amicon PM30 membrane, cation-exchange FPLC on a 
Mono Q column and nondissociating PAGE. The amino 
acid sequence was not yet known. 
The 30-kDa band was sliced from the gel after being 
stained with Coomassie Brilliant blue, digested with lysil 
endopeptidase (Achromobacter lyticus protease I) and 
separated with ODS column. A full-length cDNA clone 
was found encoding this purified native ALR. The 1.2 kb 
cDNA included a 299-bp 5' untranslated region, a 37 5-bp 
coding region, and a 550-bp 3' untranslated region. It 
encoded a protein consisting of 125 amino acids. The 
molecular weight of ALR calculated from the cDNA was 
15,081, which was consistent with the size estimated by 
SDS-PAGE under the reducing condition. The mo-
lecular weight of the purified native ALR, estimated by 
SDS-PAGE under the nonreducing condition, was about 
30,000, apparently with a homodimer structure. After 
transfection of the clone into mammalian COS cells, 
recombinant rat ALR with 125 amino acids was pro-
duced (Fig. 5). This achievement is described fully else-
where (17). 
Testing of Recombinant ALR. After the ALR ex-
pression vector was transfected into COS cells, its 
peptide product was looked for in separately collected 
supernatant and the cytosolic fraction of COS cell 
homogenate. Both collections were tested in the Eck 
fistula model as well as the Vector-COS cytosol and 
supernatant, which contained no activity (negative 
controls) (Table 6). Recombinant HGF (65), which was 
previously shown to be hepatotrophic in the Eck fistula 
model (18), was used as positive control (Table 6). 
A dose-dependent stimulation of DNA synthesis was 
detected only in the cytosolic fraction (dogs 5 and 6, 
Table 6), but not in the culture supernatant (dog 4, Ta-
ble 6). This effect on the Eck fistula liver was abolished 
by the same anti-ALR monoclonal antibody (dog 6, Table 
6) that had been used earlier (Table 4) to determine the 
specificity of the native ALR, including the most highly 
purified fraction for which the molecular weight had 
been preliminarily estimated to be 33 kDa (16). 
The recombinant ALR prevented the characteristic 
hepatocyte atrophy of Eck fistula on the treated side of 
the liver but not the other (Table 6), an effect also 
cancelled by the anti-ALR monoclonal antibody (dog 6). 
The ultrastructure of the protected hepatocytes was 
normal, whereas hepatocytes in the control (untreated) 
region of liver showed the typical damage caused by 
Eck's fistula. 
TABLE 5. Augmentation of liver regeneration 
Physicochemical characteristics 
Heat 
pH resistance 
Neuraminidase 
Trypsin 
SDS 
Reducing agents 
Immunogenicity 
Species 
Organ 
Stable > 70° C 
4.5 to 7.5 
Resistant 
Destroyed 
Resistant 
Resistant 
Yes 
Nonspecific 
Nonspecific 
ALR mRNA in rat tissues was examined by Northern 
hybridization with the entire coding region as a probe. 
Rat ALR mRNA is expressed in most tissues (heart, 
brain, spleen, lung, liver, skeletal muscle and kidney) in 
relatively low abundance, but in high abundance in the 
testis (17). The size ofmRNA of ALR is about 1.2 kb, the 
same as the cDNA. 
Other Nonhormonal Growth Factors Detected with 
the Eck Fistula Assay 
IGF II, TGF-a and HGF also have been demonstrated 
. with the Eck fistula assay to have hepatotrophic 
qualities similar to those of insulin (18). EGF was almost 
inert in the Eck fistula model, in spite of its known 
mitogenic qualities in hepatocyte tissue culture (41), and 
its chemical similarity to TGF-a, with which it has a 
common cell surface receptor (66). Of the potent 
hepatotrophic substances, only TGF-a and HGF are 
mitogenic in tissue culture (Table 1). Several other 
molecules that are mitogenic in tissue culture were 
inactive in the Eck fistula model. 
Hepatotrophic Immunosuppressants 
Cyclosporine and FK 506. These two chemically 
unrelated drugs, which have in common the prevention 
of transcription of early T -cell activation genes, augment 
posthepatectomy regeneration (67, 68) and are potently 
hepatotrophic in the Eck fistula assay (19, 20). They also 
have similar renal and neurologic side effects and are 
diabetogenic (69). How two such seemingly diverse 
agents could have similar pleiotropic actions was recon-
ciled by the discovery that both are inherently inactive 
"prodrugs" that bind to biologically "inert" cytosolic 
immunophilins. Although the immunophilin for each 
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Met Arg Thr GIn GIn Lys Arg Asp lIe Lys Phe Arg Glu Asp cys Pro 
1 5 10 15 
GIn Asp Arg Glu Glu Leu Gly Arg Asn Thr Trp Ala Phe Leu. His Thr 
20 25 30 
Leu Ala Ala Tyr Tyr Pro Asp Met Pro Thr Pro Glu GIn GIn GIn Asp 
35 40 45 
Met Ala GIn Phe lIe His lIe Phe Ser Lys Phe Tyr Pro Cys Glu Glu 
50 55 60 
Cys Ala Glu Asp lIe Arg Lys Arg lIe Asp Arg Ser GIn Pro Asp Thr 
65 70 75 80 
Ser Thr Arg Val Ser Phe Ser GIn Trp Leu Cys Arg Leu His Asn Glu 
85 90 95 
Val Asn Arg Lys Leu Gly Lys Pro Asp Phe Asp Cys Ser Arg Val Asp 
100 105 110 
Glu Arg Trp Arg Asp Gly Trp Lys Asp Gly Ser Cys Asp 
115 120 125 
FIG. 5. The amino acid sequence of rat ALR protein. This was deduced from the cDNA nucleotide sequence. Details in reference 17. 
TABLE 6. Tests in the Eck fistula assay" 
Hepatocyte size Labelled hepatocytes 
(size units) (per thousand) 
Dog no. Infusate Side infused Left Right Left Right 
1 HGF Supernatantb Left 0.156 0.088 11.0 5.3 
2 Vector-COS Cytosol (NC) Left 0.103 0.099 6.3 5.4 
3 Vector-COS Supernatant (NC) Left 0.103 0.101 3.8 4.0 
4 ALR-26 Supernatant (40 nglkg) Left 0.079 0.103 6.4 6.6 
5 ALR-26 Cytosol (40 nglkg) Left 0.163 0.090 15.2 4.8 
6 ALR-26 Cytosol (20 nglkg) to left and right + Left-right 0.150 0.104 10.1 5.1 
mAb to right 
"Infusions for 4 days immediately after the completely diverting portacaval shunt. 
bHGF: Human hepatocyte growth factor cDNA expression vector (del-HFG) was used for transfection (65). HGF previously was shown to 
be hepatotrophic (18), and this was a positive control of the assay. 
NC, negative control. 
drug has a different molecular weight, the cyclosporine-
cyclophilin and FK 506-FKBP complexes activate a 
common target, phosphatase calcineurin, which mod-
ifies the transduction of signals from the surface T-cell 
receptor to the nucleus (70). The immunophilins are 
found in all cells and are suspected by related mecha-
nisms to modulate multiple endocrinologic, immuno-
logic, growth control and chaperone-mediated pathways 
(71-73). 
A Hepatotrophic Immunophilin. The possible ex-
istence of endogenous (natural) ligand(s) for the immu-
nophilins has been raised by the demonstration that the 
inert recombinant FKBP 12 has dose-dependent hepa-
totrophic activity when tested in vivo with the Eck 
fistula assay (21). Identification of such a ligand would 
permit study of at least one natural function of the 
immunophilins that are present in essentially all cells. 
With the addition of FKBP 12' the list of hepatotrophic 
agents had grown to eight (Table 1). 
Antihepatotrophic Factors 
The Eck fistula assay also has identified two growth-
inhibitory (antihepatotrophic)· . factors that make the 
atrophy ofthe Eck fistula liver m'ore extreme and inhibit 
its characteristic low-grade hyperplasia. 
TGF-fJ. The growth factor/cytokine, TGF-/3, is phar-
macologically specific in that it cancels the hepatotrophic 
activity of coadministered TGF -a, while having no effect 
on coadministered insulin, IGF II, HGF, FK 506 or ALR 
(22). 
RPM. This potent, T -cell-directed immunosup-
pressant is closely related chemically to FK 506 and 
complexes with the same immunophilin (70). How-
ever, it has an opposite growth effect, being dramatically 
." 
.' 
: 
." 
." 
." 
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antihepatotrophic (23). The RPM-FKBP 12 complexes, 
unlike those formed by cyclosporine and FK 506, do not 
affect the phosphatase calcineurin, but prevent the 
phosphorylation of an S6 kinase (70,000) proximal to the 
ribosomes (74). Thus, RPM is immunosuppressive far 
downstream from the inhibition of nuclear transcription 
ofFK 506 and cyclosporine, acting instead by preventing 
the action of IL2 and other cytokines after their 
production (75, 76). In tissue culture, RPM selectively 
reduces the gene expression of TGF-[3 (77). 
ALR IN THE GROWfH FACTOR UNIVERSE 
Only after the testing of the recombinant ALR could 
we be sure that it was a unique growth factor. The cDNA 
has 50% homology with nuclear gene ERVI of "baker's" 
yeast, Saccharomyces cerevisiae (26). This is one of the 
few dual-function nuclear genes that is not only part of 
the mitochondrial respiratory chain, but also plays an 
independent critical role in cell growth regulation. 
Although yeasts can survive as "petite mutants" 
without oxidative phosphorylation (78), deletion of the 
ERVI gene causes a severe growth defect, decline of 
mitosis in less than 24 hr and irreversible cessation of 
cell division after 3 to 4 days (26). The ALR gene is 
suspected to be the mammalian homolog of the ERVI 
gene. 
It was previously thought that ALR was liver specific, 
but the variable RNA expression in nonhepatic tissues, 
particularly the testis (17), suggests that ALR can be 
expressed by other mitotically active cells. The effects of 
this peptide, like those of the other seven growth factors 
identifiable with the Eck fistula model, go beyond the 
augmentation of hepatocyte proliferation and mainte-
nance of cell size. All eight prevent disruption of the 
rough endoplasmic reticulum, mitochondria and other 
organelles. It is possible that these essentially identical 
end points are reached by common intermediary mo-
lecular mechanisms involving ALR. Because ALR ap-
parently is a delayed product of, not an initiator of, 
regeneration, the ALR gene could be a growth-regu-
latory gene, controlling and integrating the activities of 
other genes by modulating the production or use of their 
mRNAs. 
Nowhere is the need for such gene cross-regulation 
more clearly illustrated than by liver regeneration, with 
its bewildering profile of multiple gene activation (79). 
Without this context introduced by Jacob and Monod 
(80), it is impossible to envision how the long list of 
factors (many nonspecific) that can promote or initiate 
mitotic activity of hepatocytes in tissue culture (46, 
81-84) could result in coherent growth or regeneration 
responses. A regulatory role also has been suggested for 
insulin (85, 86). 
The complexity of regeneration and the consequent 
difficulty of drawing conclusions about individual 
growth factors from the effects of their isolated admin-
istration in vivo or their addition to hepatocyte tissue 
culture has been emphasized often by us (18, 59) and 
recently by Webber et al. (87). The value of the Eck 
fistula assay appears to be that it can identify genuinely 
important growth-related gene products or agents that 
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influence their production and action within a much 
larger collection of potential growth candidate sub-
stances screened with tissue culture techniques. 
Although their regulation is incompletely understood, 
four of the other seven known hepatotrophic substances 
(insulin, IGF II, TGF-a and HGF) and one antihepa-
totrophic molecule (TGF-[3) bind to specific cell mem-
brane receptors and become internalized tyrosine ki-
nases by autophosphorylation in the first step of signal 
transduction to the nucleus by means of further phos-
phorylation targets at tyrosine, serine and threonine 
sites (88). Although two of the remaining three (cyclo-
sporine, FK 506) as well as the antihepatotrophic 
immunosuppressant RPM have cytosolic binding sites, 
their ultimate effect also is thought to be alteration of 
signal transduction (see earlier text). 
It remains to be seen what variation (if any) of these 
patterns is followed by ALR. The Eck fistula assay 
experiments, which revealed no activity in the culture 
medium of COS cell transformant, showed that the ALR 
had remained in the cells. Because ALR lacks a stretch 
of hydrophobic amino acids, either N-terminal or in-
ternal, that could act as a signal sequence, it is not clear 
how ALR is transported across the membrane of the 
endoplasmic reticulum and is secreted. However, it is 
possible that ALR is secreted through a novel pathway, 
as has been suggested for IL-IB and thioredoxin, which 
may involve translocation of intracellular membranes, 
rather than the classic ER-Golgi route (89), depending 
on the cell types. 
Of the eight known hepatotrophic agents, only HGF 
and TGF -a unequivocally stimulate hepatocytes to 
mitosis in culture. Because ALR -belongs to the non-
stimulator group, its powerful growth effects on hepa-
tocytes in vivo may be through the regulation of 
nonparenchymal cells. If so, this will be a key link with 
leukocytes of the immune system of the kind recently 
made with insulin (86). A longstanding hypothesis of 
immunological modulation of liver regeneration by 
nonparenchymal cells (90, 91) has been supported by the 
recent observation that the onset and termination ofthe 
wave of hepatocyte mitosis in the regeneration process 
correlates with the down- and up-regulation, respec-
tively, of MHC Class II antigens in antigen-presenting 
cells and the consequent regulation (through lympho-
cytes) of gamma IFN, III and other cytokines (92). If a 
connection is made between ALR amongst other growth 
factors and leukocyte f-q.nction, the growth stimulatory 
and inhibitory effects of cyclosporine, FK 506 and RPM 
on the liver will be investigated with renewed interest. 
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